Holders of Contingent Value Rights

General Information

UMB Bank, National Association (the “Trustee”) serves as the successor Trustee under the Contingent Value Rights Agreement, dated as of November 20, 2019 (the “CVR Agreement”), by and between Bristol-Myers Squibb Company (the “Company”) and Equiniti Trust Company (the “Original Trustee”) relating to the Company’s Contingent Value Rights (the “CVRs”).

On December 18, 2020, the Trustee delivered to the Company and the Original Trustee an Instrument of Removal, Appointment and Acceptance, dated as of December 9, 2020, pursuant to which (a) the Original Trustee was removed as Trustee under the CVR Agreement, (b) the Trustee was appointed as successor Trustee under the CVR Agreement, and (c) the Trustee accepted its appointment as Trustee under the CVR Agreement. By notice dated January 4, 2021, the Company notified Holders of the CVRs of the removal of the Original Trustee and the appointment of the Trustee as successor Trustee.

The Trustee has retained Katten Muchin Rosenman LLP to represent the Trustee in connection with its role as the Trustee and with respect to matters relating to the CVR Agreement. In addition, the Trustee has retained Selendy & Gay PLLC as litigation counsel and Cahill Gordon & Reindel LLP as special counsel.

Holders of CVRs (“CVR Holders”) with questions regarding the CVRs may review the information provided in this website.

CVR Holders may also contact the Trustee in writing as follows:

UMB Bank, National Association
120 South Sixth Street, Suite 1400
Minneapolis, MN 55402
Email: BristolMyersCVR@umb.com

Please note that the Trustee may conclude that a specific response to particular inquiries from individual CVR Holders is not consistent with equal and full dissemination of information to all CVR Holders. CVR Holders should not rely on the Trustee as their sole source of information concerning the CVRs. The Trustee makes no recommendations and gives no investment, financial, legal or other advice with respect to the matters herein or as to the CVRs generally.

SUMMARY OF KEY FEATURES

    Bristol Myers-notice to holders 12-31-2020

    Bristol Myers-notice to holders 2-25-2021

    Bristol Myers-notice to holders 2-26-2021

    BMY-Holder checklist (Joinder to PFA) 3.1.2021

    Bristol Myers-notice to holders 3-09-2021

    Bristol Myers-Complaint 6-3-2021

    Bristol Myers-Complaint 6-3-2021-Exhibit A

    Bristol Myers-Complaint 6-3-2021-Exhibit B

    Bristol Myers-Complaint 6-3-2021-Exhibit C

    Bristol Myers-notice to holders 6-9-2021

    Bristol Myers–Letter to The Depository Trust Company_6-21-2021

    Bristol Myers–Letter to The Depository Trust Company_6-21-2021_Exhibit A

    Bristol Myers Memorandum of Law in Support of Motion of Defendant to Dismiss Complaint_July_23-2021_2

    Bristol_Myers_Exhibit_1_September_14-2021

    Bristol_Myers_Exhibit_2_September_14-2021

    Bristol_Myers_Exhibit_3_September_14-2021
     

    Bristol_Myers_Exhibit_4_September_14-2021

    Bristol_Myers_Exhibit_5_September_14-2021

    Bristol_Myers_Exhibit_6_September_14-2021
     

    Bristol_Myers_Exhibit_7_September_14-2021

    Bristol_Myers-DECLARATION_OF_MICHAEL_DUKE_IN_SUPPORT_OF_PLAINTIFFS_OPPOSITION TO_DEFENDANTS_MOTION_TO_DISMISS_Sept_14-2021

    Bristol_Myers-OPPOSITION_TO_DEFENDANTS_MOTION_TO_DISMISS_Sept_14-2021

    Bristol_Myers_Reply_Memorandum_in_Further_Support_of_Motion_to_Dismiss_the_Complaint_October_14-2021

    Bristol_Myers-notice_to_holders_5-19-2022

    Bristol_Myers_-_Memorandum_Opinion_and_Order_-_June_24_2022

    Bristol-Myers_-_Notice_to_Holders_-_July_8_2022

    Bristol-Myers_-_Answer_July_8_2022

    Bristol_Myers-Civil_Case_Management_Plan_and_Scheduling_Order-2022-07-26

    Bristol Myers – Joint Status Letter – January 26-2023

    Bristol Myers – Notice to Holders – February 15-2023

    Updating Scheduling Order dated 8.3.23

    Bristol-Myers Notice to Holders November 1 2023

    Joint Status Update dated 10.19.23

    12.15.23_Order_Granting_Leave_to_File_Summary_Judgment_Motion

    BMY-Notice_to_Holders_Feb-2024

    2.2.24_BMY_Memo_in_Support_of_Second_Motion_to_Dismiss

    2.2.24_BMY_Second_Motion_to_Dismiss

    UMB OPPOSITION TO BMS MOTION TO DISMISS-March 15, 2024

    Bristol Myers Reply Memorandum ISO MTD - April_5, 2024

    Order Extending Scheduling Order - April 12, 2024

    UMB Bank's Supplemental Opposition to Motion to Dismiss - April 29, 2024

    Bristol Myers Supplemental Brief in Support of Motion to Dismiss - May 6, 2024

    This section provides web-links to third party sites and information which may be of interest to Holders of Contingent Value Rights. UMB does not monitor the information contained on these third-party websites and cannot verify the content or accuracy of such sites and information contained.

    Bristol-Myers Squibb CVR Agreement - Nov 20-2019